Standard Psoriasis Treatment Significantly Reduces Insomnia and Improves Sleep Quality: Study
A recent prospective observational study reveals that standard non-biological therapies dramatically restore rest for psoriasis patients, slashing clinical insomnia from 25.4% to a mere 3.4% over three months, as published in the Indian Dermatology Online Journal in March-April 2026.
While psoriasis is increasingly acknowledged as a systemic inflammatory condition frequently linked to various psychiatric comorbidities, including sleep disturbances that affect up to 85.4% of patients, a significant research gap exists regarding these patterns within the Indian subcontinent. To address this, Dr. Neirita Hazarika from the All India Institute of Medical Sciences (AIIMS), Guwahati, led a team to evaluate the prevalence of sleep impairment and the restorative potential of standard, non-biological treatment protocols using tools like the Psoriasis Area Severity Index (PASI).
Therefore, the prospective observational study monitored 59 adult patients with chronic plaque psoriasis over 12 weeks at a tertiary center to evaluate the primary endpoints of sleep quality and insomnia changes using the Pittsburgh Sleep Quality Index (PSQI), the Insomnia Severity Index (ISI), and the 5-D Itch Scale. By excluding individuals with confounding mental health medications or pregnancies, the researchers assessed the impact of standard topical and systemic nonbiological interventions through analytical methods, including repeated measures analysis of variance, to ensure data accuracy.
Key Clinical Findings of the Study Include:
Insomnia Resolution: In the study, the prevalence of clinical insomnia saw a steep decline from 25.4% at the start of the study to only 3.4% by the final week.
Quality Enhancements: Poor sleep quality, which initially troubled 10.2% of the participants, was successfully reduced to 5.1% through the consistent application of standard therapeutic regimens.
Pruritus Linkage: Reportedly, the study found a significant positive correlation between improved sleep and the reduction of the 5-D Itch Scale scores (P < 0.001), highlighting that managing skin irritation is central to restorative rest.
Disease Severity: Higher baseline scores on the Psoriasis Area Severity Index were strongly associated with the presence of insomnia (P < 0.001), suggesting that more extensive skin involvement directly compromises sleep.
Early Efficacy: Reportedly, substantial improvements in sleep parameters were documented as early as the four-week mark, indicating that patients may experience rapid symptomatic relief shortly after initiating non-biological care.
The results suggest that standard non-biological treatments, which are essential in resource-limited settings, are highly effective in mitigating sleep disorders, as evidenced by clinical insomnia rates dropping to 3.4% and poor sleep quality being halved by the study's conclusion.
These findings suggest that healthcare providers can effectively utilize traditional topical and systemic therapies to address both skin symptoms and associated sleep disturbances in patients with psoriasis.
Although the research was constrained by a 12-week observation window and a high rate of participant attrition, it highlights the necessity for larger, long-term studies that incorporate improved patient retention strategies to further explore these sleep-related benefits.
Reference
Hazarika N, Bhatia R, Sarkar N, Vasisht S, Kansal NK, Gupta R. Sleep disorders in psoriasis and the effect of treatment on sleep quality: A prospective study in a resource-poor setting. Indian Dermatol Online J 2026;17:215-9.
